Skip to Content
Merck
All Photos(1)

Key Documents

Y0000429

Trospium chloride

European Pharmacopoeia (EP) Reference Standard

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C25H30ClNO3
CAS Number:
10405-02-4
Molecular Weight:
427.96
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

trospium

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

InChI

1S/C25H30NO3.ClH/c27-24(25(28,19-9-3-1-4-10-19)20-11-5-2-6-12-20)29-23-17-21-13-14-22(18-23)26(21)15-7-8-16-26;/h1-6,9-12,21-23,28H,7-8,13-18H2;1H/q+1;/p-1

InChI key

RVCSYOQWLPPAOA-UHFFFAOYSA-M

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Trospium chloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Abdurrahman Karaman et al.
Urology, 82(1), 194-200 (2013-03-05)
To examine the efficacy of trospium chloride and tolterodine on the renal parenchymal inflammatory process and upper urinary dilation in rats with chronic partial upper urinary tract obstruction. A total of 32 rats were divided into 4 groups: group 1
M Haupt et al.
Journal of controlled release : official journal of the Controlled Release Society, 170(2), 161-166 (2013-06-05)
The overactive bladder (OAB) is a common disease with an overactivity of the detrusor muscle in the bladder wall. Besides peroral administration of anticholinergic drugs and bladder irrigations, there is a need for a sustained release formulation in the urinary
Serap Kaya et al.
Clinical rehabilitation, 25(4), 327-338 (2010-10-15)
To investigate and compare the effectiveness of various treatment protocols for the treatment of women with idiopathic detrusor overactivity. Prospective, randomized controlled trial. Departments of Physiotherapy and Rehabilitation and Obstetrics and Gynaecology, Hacettepe University. Forty-six subjects were randomized to three
Birger Wenge et al.
Naunyn-Schmiedeberg's archives of pharmacology, 383(2), 203-208 (2011-01-08)
The muscarinic antagonists oxybutynin and trospium are used as spasmolytic agents for the treatment of overactive urinary bladder disease. Recently, it has been shown that trospium, but not oxybutynin, is a substrate of the multidrug efflux carrier P-glycoprotein, but carrier-mediated
David A Ginsberg et al.
Neurourology and urodynamics, 30(4), 563-567 (2011-01-27)
Once-daily extended release (XR) trospium chloride, which provides therapeutic trospium plasma concentrations over 24 hours, has demonstrated efficacy in treating overactive bladder (OAB) symptoms as evaluated over a 24-hr period. This analysis examined the effects of trospium XR on diurnal
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service